|
US6660753B2
(en)
|
1999-08-19 |
2003-12-09 |
Nps Pharmaceuticals, Inc. |
Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
MXPA03007513A
(es)
*
|
2001-02-21 |
2004-07-30 |
Nps Pharma Inc |
Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
|
|
US6916821B2
(en)
|
2001-04-02 |
2005-07-12 |
Brown University |
Methods of treating disorders with Group I mGluR antagonists
|
|
DE60214846T2
(de)
*
|
2001-04-02 |
2007-05-16 |
Brown University Research Foundation |
Verwendung von mGLuR5 antagonists zur Herstellung von Medikamenten zur Behandlung von empfindlichen X Syndrome, Autismus und geistiger Zurückgebliebenheit
|
|
DE60223720T2
(de)
*
|
2001-12-18 |
2008-10-30 |
Merck & Co., Inc. |
Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5
|
|
DE60222698T2
(de)
*
|
2001-12-18 |
2008-06-19 |
Merck & Co., Inc. |
Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
|
|
WO2003053922A2
(en)
*
|
2001-12-19 |
2003-07-03 |
Merck & Co., Inc. |
Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
|
|
EP1485093B1
(en)
*
|
2002-03-12 |
2010-11-03 |
Merck Sharp & Dohme Corp. |
Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
|
|
SE0201943D0
(sv)
*
|
2002-06-20 |
2002-06-20 |
Astrazeneca Ab |
New use
|
|
US7964609B2
(en)
|
2002-06-20 |
2011-06-21 |
Astrazeneca Ab |
Use of mGluR5 antagonists for the treatment of gerd
|
|
TW200424183A
(en)
*
|
2002-08-09 |
2004-11-16 |
Nps Pharma Inc |
New compounds
|
|
US7074809B2
(en)
|
2002-08-09 |
2006-07-11 |
Astrazeneca Ab |
Compounds
|
|
WO2004014881A2
(en)
|
2002-08-09 |
2004-02-19 |
Astra Zeneca Ab |
'1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
|
|
GB0303503D0
(en)
*
|
2003-02-14 |
2003-03-19 |
Novartis Ag |
Organic compounds
|
|
EP1613617A4
(en)
*
|
2003-04-04 |
2009-02-18 |
Merck & Co Inc |
METABOTROPIC GLUTAMATE RECEPTOR-5 DIARYLSUBSTITUTED TRIAZOLE MODULATORS
|
|
AU2004240586A1
(en)
*
|
2003-05-15 |
2004-12-02 |
Merck & Co., Inc. |
3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
|
|
WO2005060961A2
(en)
*
|
2003-12-18 |
2005-07-07 |
Astrazeneca Ab |
Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
|
|
JP4958560B2
(ja)
*
|
2003-12-24 |
2012-06-20 |
プロシディオン・リミテッド |
Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
|
|
DE602005008558D1
(de)
*
|
2004-02-18 |
2008-09-11 |
Astrazeneca Ab |
Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
|
|
US7585881B2
(en)
|
2004-02-18 |
2009-09-08 |
Astrazeneca Ab |
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
US20070185100A1
(en)
*
|
2004-02-18 |
2007-08-09 |
Astrazeneca Ab |
Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
TW200538108A
(en)
|
2004-02-19 |
2005-12-01 |
Astrazeneca Ab |
Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
US7858800B2
(en)
*
|
2004-06-30 |
2010-12-28 |
Banyu Pharmaceutical Co., Ltd. |
Biaryl derivatives
|
|
KR100621192B1
(ko)
*
|
2004-10-13 |
2006-09-19 |
한국화학연구원 |
무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법
|
|
JP4557685B2
(ja)
|
2004-11-15 |
2010-10-06 |
独立行政法人理化学研究所 |
蛍光蛋白質
|
|
BRPI0606644A2
(pt)
|
2005-01-14 |
2009-07-14 |
Hoffmann La Roche |
derivados de 4-carboxamida tiazola
|
|
GB0510142D0
(en)
*
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds A1
|
|
CN101203220A
(zh)
*
|
2005-06-28 |
2008-06-18 |
阿斯利康(瑞典)有限公司 |
新用途
|
|
PL1907382T3
(pl)
|
2005-07-26 |
2016-01-29 |
Bial Portela & Ca Sa |
Pochodne nitrokatecholowe jako inhibitory COMT
|
|
UY29796A1
(es)
|
2005-09-29 |
2007-04-30 |
Astrazeneca Ab |
Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
|
|
RU2425834C2
(ru)
|
2005-11-08 |
2011-08-10 |
Ф. Хоффманн-Ля Рош Аг |
ПРОИЗВОДНЫЕ ТИАЗОЛО[4,5-c]ПИРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРОВ mGluR5
|
|
US7951824B2
(en)
|
2006-02-17 |
2011-05-31 |
Hoffman-La Roche Inc. |
4-aryl-pyridine-2-carboxyamide derivatives
|
|
PL2003132T3
(pl)
*
|
2006-04-03 |
2014-10-31 |
Astellas Pharma Inc |
Pochodne oksadiazolu jako agoniści S1P1
|
|
EP1845097A1
(en)
|
2006-04-10 |
2007-10-17 |
Portela & Ca., S.A. |
Oxadiazole derivatives as COMT inhibitors
|
|
WO2008028903A2
(en)
*
|
2006-09-04 |
2008-03-13 |
Neurosearch A/S |
Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
|
|
PT2069336E
(pt)
|
2006-09-07 |
2013-03-07 |
Actelion Pharmaceuticals Ltd |
Derivados de piridin-4-ilo como agentes imunomoduladores
|
|
PL2069335T3
(pl)
|
2006-09-08 |
2013-05-31 |
Actelion Pharmaceuticals Ltd |
Pochodne pirydyn-3-ylu jako środki immunomodulujące
|
|
ES2393412T3
(es)
|
2006-09-21 |
2012-12-21 |
Actelion Pharmaceuticals Ltd. |
Derivados de fenilo y su uso como inmunomoduladores
|
|
BRPI0721213B1
(pt)
|
2007-01-31 |
2021-11-09 |
Bial - Portela & Ca, S.A. |
Uso de nitrocatecóis substituídos, e embalagem
|
|
BRPI0808789A2
(pt)
|
2007-03-16 |
2014-08-12 |
Actelion Pharmaceuticals Ltd |
Compostos e composição farmacêutica de derivados aminopiridina e uso destes
|
|
PT2195311E
(pt)
|
2007-08-17 |
2011-05-25 |
Actelion Pharmaceuticals Ltd |
Derivados de piridina como moduladores do receptor s1p1/edg1
|
|
JP2011502148A
(ja)
|
2007-10-31 |
2011-01-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
|
|
KR20100092473A
(ko)
|
2007-11-01 |
2010-08-20 |
액테리온 파마슈티칼 리미티드 |
신규한 피리미딘 유도체
|
|
CN101903356B
(zh)
*
|
2007-12-20 |
2013-05-22 |
拜耳知识产权有限责任公司 |
4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用
|
|
US8188131B2
(en)
|
2008-02-07 |
2012-05-29 |
Massachusetts Eye & Ear Infirmary |
Compounds that enhance Atoh1 expression
|
|
CA2715317A1
(en)
|
2008-03-07 |
2009-09-11 |
Actelion Pharmaceuticals Ltd |
Novel aminomethyl benzene derivatives
|
|
WO2009116882A1
(en)
|
2008-03-17 |
2009-09-24 |
Portela & Ca., S.A. |
Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol
|
|
MX2011004570A
(es)
|
2008-10-31 |
2011-06-17 |
Merck Sharp & Dohme |
Antagonistas del receptor p2x3 para el tratamiento del dolor.
|
|
DE102008057344A1
(de)
|
2008-11-14 |
2010-05-20 |
Bayer Schering Pharma Aktiengesellschaft |
Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102009041241A1
(de)
|
2009-09-11 |
2011-08-04 |
Bayer Schering Pharma Aktiengesellschaft, 13353 |
Substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102009041242A1
(de)
|
2009-09-11 |
2011-12-15 |
Bayer Schering Pharma Aktiengesellschaft |
Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102008057364A1
(de)
|
2008-11-14 |
2010-05-20 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102008057343A1
(de)
|
2008-11-14 |
2010-05-20 |
Bayer Schering Pharma Aktiengesellschaft |
Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
|
|
AU2010229142A1
(en)
|
2009-03-23 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
P2X3, receptor antagonists for treatment of pain
|
|
US8569512B2
(en)
|
2009-03-23 |
2013-10-29 |
Merck Sharp & Dohme Corp. |
P2X3 receptor antagonists for treatment of pain
|
|
WO2010111059A1
(en)
|
2009-03-23 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
P2x3 receptor antagonists for treatment of pain
|
|
PT2413912T
(pt)
|
2009-04-01 |
2019-06-11 |
Bial Portela & Ca Sa |
Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir
|
|
AU2010236685A1
(en)
*
|
2009-04-13 |
2011-12-01 |
Irm Llc |
Compositions and methods for modulating retinol binding to retinol binding protein 4 (RBP4)
|
|
CA2767585C
(en)
|
2009-07-16 |
2017-09-26 |
Actelion Pharmaceuticals Ltd |
Pyridin-4-yl derivatives
|
|
WO2011109398A2
(en)
|
2010-03-02 |
2011-09-09 |
President And Fellows Of Harvard College |
Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
|
|
MA34910B1
(fr)
|
2011-01-19 |
2014-02-01 |
Actelion Pharmaceuticals Ltd |
Dérivés de 2-methoxy-pyridin-4-yl
|
|
US20140045900A1
(en)
|
2011-02-11 |
2014-02-13 |
Bial-Portela & Ca, S.A. |
Administration regime for nitrocatechols
|
|
JP6456143B2
(ja)
|
2011-12-13 |
2019-01-23 |
ノヴィファーマ，エス．アー． |
カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
|
|
JP5946288B2
(ja)
*
|
2012-02-24 |
2016-07-06 |
公立大学法人名古屋市立大学 |
新規ヒドロキサム酸誘導体及びその用途
|
|
US9232800B2
(en)
|
2013-02-15 |
2016-01-12 |
Monsanto Technology Llc |
3,5-disubstituted-4,5-dihydro-1,2,4-oxadiazoles and compositions and methods for controlling nematode pests
|
|
EP2853532B1
(en)
*
|
2013-09-28 |
2020-12-09 |
Instytut Farmakologii Polskiej Akademii Nauk |
1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
|
|
RU2017120184A
(ru)
|
2014-11-28 |
2018-12-28 |
БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. |
Лекарства для замедления течения болезни паркинсона
|
|
PH12017502097B1
(en)
|
2015-05-20 |
2023-05-05 |
Idorsia Pharmaceuticals Ltd |
Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
|
|
AU2016281346B2
(en)
|
2015-06-23 |
2020-01-02 |
Kissei Pharmaceutical Co., Ltd. |
Pyrazole derivative, or pharmaceutically acceptable salt thereof
|
|
EP3436009B1
(en)
*
|
2016-03-30 |
2024-03-06 |
Sinntaxis AB |
Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages.
|
|
FI3904350T3
(fi)
*
|
2018-04-12 |
2023-11-15 |
Bayer Ag |
N-(syklopropyylimetyyli)-5-(metyylisulfonyyli)-n-{1-[1-(pyrimidin-2-yyli)-1h-1,2,4-triatsol-5-yyli]etyyli}bentsamidijohdannaisia ja vastaavia pyridiinikarboksamidijohdannaisia tuholaistorjunta-aineina
|
|
KR102276327B1
(ko)
*
|
2019-06-25 |
2021-07-12 |
연세대학교 산학협력단 |
신규 옥사다이아졸 화합물 및 이를 포함하는 당뇨 예방 또는 치료용 조성물
|
|
AU2020341464A1
(en)
*
|
2019-09-05 |
2022-04-21 |
Trevena, Inc. |
Methods of treating epilepsy using the same
|